Gold Glyconanoparticles Combined with 91–99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors
Authors:
- Hector Terán-NavarroHTHector Terán-Navarro
- Andrea ZeoliAZAndrea Zeoli
- David Salines-CuevasDSDavid Salines-Cuevas
- Marco MarradiMMMarco Marradi
- Noemi MontoyaNMNoemi Montoya
- Elena Gonzalez-LopezEGElena Gonzalez-Lopez
- Javier Gonzalo Ocejo-VinyalsJavier Gonzalo Ocejo-Vinyals
- Mario Dominguez-EstebanMDMario Dominguez-Esteban
- Jose Luis Gutierrez-BañosJGJose Luis Gutierrez-Baños
- Felix Campos-JuanateyFCFelix Campos-Juanatey
- Sonsoles Yañez-DiazSYSonsoles Yañez-Diaz
- Almudena Garcia-CastañoAGAlmudena Garcia-Castaño
Open Access
Abstract
This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed adjuvant abilities as they induce maturation and activation of monocyte-derived dendritic cells (MoDCs) to functional antigen-presenting cells in healthy donors and patients with melanoma or bladder cancer (BC), promoting a Th1 cytokine pattern. GNP-LLO91–99 nanovaccines were also efficient dendritic cell inducers of immunogenic tumor death using different bladder and melanoma tumor cell lines. The establishment of a pre-clinical mice model of subcutaneous BC confirmed that a single dose of GNP-LLO91–99 nanovaccines reduced tumor burden 4.7-fold and stimulated systemic Th1-type immune responses. Proof of concept assays validated GNP-LLO91–99 nanovaccines as immunotherapy by comparison to anti-CTLA-4 or anti-PD-1 antibodies. In fact, GNP-LLO91–99 nanovaccines increased percentages of CD4+ and CD8+ T cells, B cells, and functional antigen-presenting DCs in tumor-infiltrated lymphocytes, while they reduced the levels of myeloid-derived suppressor cells (MDSC) and suppressor T cells (Treg). We conclude that GNP-LLO91–99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma.Keywords
Funding Information
- the CICYT program of the Ministry of Science and Innovation (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
- European FEDER funds “A new way of making Europe” and the COST European action ENOVA (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
- Instituto de Salud Carlos III (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
- the Bio-Health Research Program of Cantabria Government (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
- MIUR-Italy (“Progetto Dipartimenti di Eccellenza 2018–2022”, allocated to Department of Chemistry “Ugo Schiff”) (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
- the COST European action INNOGLY (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
This publication has 33 references indexed in Scilit:
- Novel nanoparticle vaccines for ListeriosisHuman Vaccines & Immunotherapeutics, 2015
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic CancerJournal of Clinical Oncology, 2015
- A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infectionVaccine, 2015
- Biological Effects of Listeriolysin O: Implications for VaccinationBioMed Research International, 2015
- Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancerExperimental and Therapeutic Medicine, 2014
- Increased Numbers of Monocyte-Derived Dendritic Cells during Successful Tumor Immunotherapy with Immune-Activating AgentsThe Journal of Immunology, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Glyconanoparticles as multifunctional and multimodal carbohydrate systemsChemical Society Reviews, 2013
- Gold Manno‐Glyconanoparticles: Multivalent Systems to Block HIV‐1 gp120 Binding to the Lectin DC‐SIGNChemistry – A European Journal, 2009
- Cancer immunotherapy using Listeria monocytogenes and listerial virulence factorsImmunologic Research, 2008